TY - JOUR
T1 - Treatment of Sulfur Mustard Corneal Injury by Augmenting the DNA Damage Response (DDR)
T2 - A Novel Approach
AU - Shalwitz, Robert
AU - Day, Tovah
AU - Ruehlmann, Anna Kotsakis
AU - Julio, Lindsay
AU - Gordon, Shellaina
AU - Vandeuren, Adrianna
AU - Nelson, Marian
AU - Lyman, Megan
AU - Kelly, Kyle
AU - Altvater, Amber
AU - Ondeck, Celinia
AU - O’Brien, Sean
AU - Hamilton, Tracey
AU - Hanson, Ryan L.
AU - Wayman, Kayla
AU - Miller, Alexandrea
AU - Shalwitz, Isaiah
AU - Batchelor, Eric
AU - McNutt, Patrick
N1 - Publisher Copyright:
© 2024 American Society for Pharmacology and Experimental Therapy (ASPET). All rights reserved.
PY - 2024/2/1
Y1 - 2024/2/1
N2 - Sulfur mustard (SM) is a highly reactive organic chemical has been used as a chemical warfare agent and terrorist threat since World War I. The cornea is highly sensitive to SM toxicity and exposure to low vapor doses can cause incapacitating acute injuries. Exposure to higher doses can elicit persistent secondary keratopathies that cause reduced quality of life and impaired or lost vision. Despite a century of research, there are no specific treatments for acute or persistent ocular SM injuries. SM cytotoxicity emerges, in part, through DNA alkylation and double-strand breaks (DSBs). Because DSBs can naturally be repaired by DNA damage response pathways with low efficiency, we hypothesized that enhancing the homologous recombination pathway could pose a novel approach to mitigate SM injury. Here, we demonstrate that a dilithium salt of adenosine diphosphoribose (INV-102) increases protein levels of p53 and Sirtuin 6, upregulates transcription of BRCA1/2, enhances cH2AX focus formation, and promotes assembly of repair complexes at DSBs. Based on in vitro evidence showing INV-102 enhancement of DNA damage response through both p53-dependent and p53-independent pathways, we next tested INV-102 in a rabbit preclinical model of corneal injury. In vivo studies demonstrate a marked reduction in the incidence and severity of secondary keratopathies in INV-102treated eyes compared with vehicle-treated eyes when treatment was started 24 hours after SM vapor exposure. These results suggest DNA repair mechanisms are a viable therapeutic target for SM injury and suggest topical treatment with INV-102 is a promising approach for SM as well as other conditions associated with DSBs.
AB - Sulfur mustard (SM) is a highly reactive organic chemical has been used as a chemical warfare agent and terrorist threat since World War I. The cornea is highly sensitive to SM toxicity and exposure to low vapor doses can cause incapacitating acute injuries. Exposure to higher doses can elicit persistent secondary keratopathies that cause reduced quality of life and impaired or lost vision. Despite a century of research, there are no specific treatments for acute or persistent ocular SM injuries. SM cytotoxicity emerges, in part, through DNA alkylation and double-strand breaks (DSBs). Because DSBs can naturally be repaired by DNA damage response pathways with low efficiency, we hypothesized that enhancing the homologous recombination pathway could pose a novel approach to mitigate SM injury. Here, we demonstrate that a dilithium salt of adenosine diphosphoribose (INV-102) increases protein levels of p53 and Sirtuin 6, upregulates transcription of BRCA1/2, enhances cH2AX focus formation, and promotes assembly of repair complexes at DSBs. Based on in vitro evidence showing INV-102 enhancement of DNA damage response through both p53-dependent and p53-independent pathways, we next tested INV-102 in a rabbit preclinical model of corneal injury. In vivo studies demonstrate a marked reduction in the incidence and severity of secondary keratopathies in INV-102treated eyes compared with vehicle-treated eyes when treatment was started 24 hours after SM vapor exposure. These results suggest DNA repair mechanisms are a viable therapeutic target for SM injury and suggest topical treatment with INV-102 is a promising approach for SM as well as other conditions associated with DSBs.
UR - http://www.scopus.com/inward/record.url?scp=85182957029&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85182957029&partnerID=8YFLogxK
U2 - 10.1124/jpet.123.001686
DO - 10.1124/jpet.123.001686
M3 - Article
C2 - 37977813
AN - SCOPUS:85182957029
SN - 0022-3565
VL - 388
SP - 526
EP - 535
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
IS - 2
ER -